Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Peijia Medical Ltd. ( (HK:9996) ) has provided an update.
Peijia Medical Limited announced that it has received approval from the National Medical Products Administration of China for its TaurusTrio Transcatheter Aortic Valve (TAV) system. This system, designed to treat severe aortic regurgitation, addresses a significant unmet medical need in China by providing a treatment option for patients who lack calcification for traditional valve anchoring. The approval marks a significant step for Peijia Medical in expanding its market presence and offering advanced medical solutions in China.
The most recent analyst rating on (HK:9996) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Limited is a company incorporated in the Cayman Islands, operating in the medical device industry. It focuses on developing and manufacturing innovative medical products, particularly in the field of transcatheter heart valve systems.
Average Trading Volume: 1,482,843
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.87B
Learn more about 9996 stock on TipRanks’ Stock Analysis page.